Open Orphan PLC Exercise of Warrants and Issue of Shares (3463N)
September 23 2019 - 10:39AM
UK Regulatory
TIDMORPH
RNS Number : 3463N
Open Orphan PLC
23 September 2019
23 September 2019
Open Orphan Plc
("Open Orphan" or the "Company")
Exercise of Warrants and Issue of Shares
Open Orphan, a European-focussed, rare and orphan drug
consulting services platform, announces that the Company has
received notices of exercise of warrants over 539,654 ordinary
shares of 0.1 pence each in the capital of the Company ("Ordinary
Shares") at a price of 0.1 pence per share for 191,051 ordinary
shares and at a price of 2.2 pence per share for 348,603 ordinary
shares. The gross proceeds of this exercise received by the Company
amounts to GBP7,860.33.
Following the warrant exercise, the outstanding warrants over
Ordinary Shares are as follows:
Number of Ordinary Shares Exercise Price per Expiry Date
share
-------------------------- ------------------- -----------------
166,666 30 pence 6 June 2021
1,759,752 0.1 pence 10 December 2023
3,210,940 2.2 pence 10 December 2023
1,607,142 5.6 pence 27 June 2024
Total Voting Rights
The Company has made application for 539,654 new Ordinary
Shares, to be issued and allotted as a result of the warrant
exercise set out above, to be admitted to trading on AIM and
Euronext Growth. Admission is expected to occur at 8.00 a.m. on 27
September 2019.
Following the admission of 539,654 new Ordinary Shares, the
Company's total issued ordinary share capital will consist of
254,572,567 Ordinary Shares. This figure may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the Financial
Conduct Authority's Disclosure Guidance and Transparency Rules.
Enquiries:
Open Orphan Plc Tel: +353 1 644 0007
Cathal Friel, Chief Executive Officer
Arden Partners (Nominated Adviser and Joint Broker) Tel: +44
(0)20 7614 5900
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer
Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1
679 6363
Anthony Farrell (Corporate Finance)
Camarco (Financial PR) Tel: +44 (0)20 3757 4980
Tom Huddart / Billy Clegg / Daniel Sherwen
Notes to Editors:
Open Orphan plc is a European-focussed, rare and orphan drug
consulting services platform. The Company consists of four
elements: a European clinical research organisation and
consultancy; an orphan drug services business; a Virtual Rep and
Data Access Platform consisting of physicians and key opinion
leaders; and a Health Data Platform to partner with Patient
Advocacy Groups. The Company is targeting rapid growth in one of
the fastest growing sectors in the global pharmaceutical industry
targeting under-supplied treatment for life threatening or very
serious diseases and rare disorders.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEZXLFLKKFXBBD
(END) Dow Jones Newswires
September 23, 2019 10:39 ET (14:39 GMT)
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Sep 2023 to Sep 2024